The DELIVER Trial

It has been reported at the 2022 European Society of Cardiology Congress that the DELIVER trial has met its primary outcome - a relative reduction of 18% in a composite of worsening heart failure (HF) or cardiovascular death. These results, added to evidence from previously reported pivotal trials w...

Descripción completa

Detalles Bibliográficos
Autor: Bayés-Genís, Antoni|||0000-0002-3044-197X
Tipo de recurso: artículo
Fecha de publicación:2022
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:273232
Acceso en línea:https://ddd.uab.cat/record/273232
https://dx.doi.org/urn:doi:10.15420/ecr.2022.44
Access Level:acceso abierto
Palabra clave:Heart failure
Dapagliflozin
Ejection fraction
Natriuretic peptides
Diagnosis
Sodium-glucose cotransporter-2 inhibitors
id ES_ec5b34e19b44f9df942591183f8b6830
oai_identifier_str oai:ddd.uab.cat:273232
network_acronym_str ES
network_name_str España
repository_id_str
spelling The DELIVER Trialthe Beginning of the End of Ejection Fraction TyrannyBayés-Genís, Antoni|||0000-0002-3044-197XHeart failureDapagliflozinEjection fractionNatriuretic peptidesDiagnosisSodium-glucose cotransporter-2 inhibitorsIt has been reported at the 2022 European Society of Cardiology Congress that the DELIVER trial has met its primary outcome - a relative reduction of 18% in a composite of worsening heart failure (HF) or cardiovascular death. These results, added to evidence from previously reported pivotal trials with sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with reduced and preserved heart failure (HF), provide compelling evidence of the benefit of SGLT2is across the HF spectrum, irrespective of ejection fraction. New diagnostic algorithms that are quick and easy to implement at the point of care are needed for quick diagnosis and implementation of these drugs. Ejection fraction may come later for proper phenotyping. 22022-01-0120222022-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/273232https://dx.doi.org/urn:doi:10.15420/ecr.2022.44reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:2732322026-06-06T12:50:31Z
dc.title.none.fl_str_mv The DELIVER Trial
the Beginning of the End of Ejection Fraction Tyranny
title The DELIVER Trial
spellingShingle The DELIVER Trial
Bayés-Genís, Antoni|||0000-0002-3044-197X
Heart failure
Dapagliflozin
Ejection fraction
Natriuretic peptides
Diagnosis
Sodium-glucose cotransporter-2 inhibitors
title_short The DELIVER Trial
title_full The DELIVER Trial
title_fullStr The DELIVER Trial
title_full_unstemmed The DELIVER Trial
title_sort The DELIVER Trial
dc.creator.none.fl_str_mv Bayés-Genís, Antoni|||0000-0002-3044-197X
author Bayés-Genís, Antoni|||0000-0002-3044-197X
author_facet Bayés-Genís, Antoni|||0000-0002-3044-197X
author_role author
dc.subject.none.fl_str_mv Heart failure
Dapagliflozin
Ejection fraction
Natriuretic peptides
Diagnosis
Sodium-glucose cotransporter-2 inhibitors
topic Heart failure
Dapagliflozin
Ejection fraction
Natriuretic peptides
Diagnosis
Sodium-glucose cotransporter-2 inhibitors
description It has been reported at the 2022 European Society of Cardiology Congress that the DELIVER trial has met its primary outcome - a relative reduction of 18% in a composite of worsening heart failure (HF) or cardiovascular death. These results, added to evidence from previously reported pivotal trials with sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with reduced and preserved heart failure (HF), provide compelling evidence of the benefit of SGLT2is across the HF spectrum, irrespective of ejection fraction. New diagnostic algorithms that are quick and easy to implement at the point of care are needed for quick diagnosis and implementation of these drugs. Ejection fraction may come later for proper phenotyping.
publishDate 2022
dc.date.none.fl_str_mv 2
2022-01-01
2022
2022-01-01
dc.type.none.fl_str_mv Article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/273232
https://dx.doi.org/urn:doi:10.15420/ecr.2022.44
url https://ddd.uab.cat/record/273232
https://dx.doi.org/urn:doi:10.15420/ecr.2022.44
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869423307622711296
score 15,301603

Similares en LA Referencia